Vanda Pharmaceuticals (VNDA) Stock Highlights

4.78 | +3.24%

2024-12-21 05:58:45

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765.

Statistics

Range Today

4.59 4.83

Volume Today 926.4K

Range 1 Year

3.46 6.75

Volume 1 Year 309.05M

Range 3 Year

3.3 18

Volume 3 Year 638.34M

Range 10 Year

3.3 33.44

Volume 10 Year 1.78B

Highlights

Market Capitalization 302.62M (small)

Floating Shares 52.49M

Current Price 4.78

Price To Earnings -25.2

Price To Revenue -0.36

Price To Book 0.56

Earnings Per Share -0.2

Payout Ratio 0%

Performance

Latest +3.24%

1 Month -2.45%

3 Months +3.91%

6 Months -19.12%

1 Year +19.5%

3 Years -71.14%

5 Years -71.45%

10 Years -60.95%

Benchmarks

Market Capitalization

210 / 368

Gross Profits

28 / 278

Total Revenue

58 / 300

Total Rank

27 / 368

Free Cashflow

25 / 352

Performance 5 years

208 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.